Stereotaxis (NYSEAMERICAN:STXS) Stock Price Down 1.6% – Here’s What Happened

Stereotaxis Inc. (NYSEAMERICAN:STXS) shares dropped 1.6% during mid-day trading on Wednesday . The stock traded as low as $2.47 and last traded at $2.49. Approximately 297,657 shares traded hands during trading, a decline of 45% from the average daily volume of 544,622 shares. The stock had previously closed at $2.53.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on STXS shares. Roth Mkm reissued a “buy” rating and set a $4.00 target price on shares of Stereotaxis in a report on Wednesday, November 12th. UBS Group set a $4.00 price objective on shares of Stereotaxis in a research report on Wednesday, November 5th. Citigroup started coverage on shares of Stereotaxis in a report on Tuesday, December 16th. They issued an “outperform” rating on the stock. Finally, Citizens Jmp initiated coverage on Stereotaxis in a research note on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $4.00.

Stereotaxis Stock Down 1.6%

The firm has a market cap of $232.37 million, a P/E ratio of -8.89 and a beta of 1.44. The stock’s 50-day moving average is $2.46 and its 200-day moving average is $2.64.

Insider Buying and Selling at Stereotaxis

In other news, Director Paul J. Isaac bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were acquired at an average cost of $2.24 per share, with a total value of $44,800.00. Following the completion of the transaction, the director directly owned 2,786,557 shares in the company, valued at $6,241,887.68. This represents a 0.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 17.77% of the company’s stock.

Institutional Trading of Stereotaxis

Several institutional investors have recently made changes to their positions in STXS. SG Americas Securities LLC bought a new position in Stereotaxis during the fourth quarter worth about $33,000. BNP Paribas Financial Markets grew its stake in shares of Stereotaxis by 106.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after purchasing an additional 5,910 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Stereotaxis in the 3rd quarter worth approximately $38,000. Moneta Group Investment Advisors LLC bought a new position in shares of Stereotaxis during the 3rd quarter worth approximately $43,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Stereotaxis during the 3rd quarter worth approximately $54,000. 45.35% of the stock is currently owned by institutional investors and hedge funds.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.